Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Crenolanib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 known ✓ | P36888 | 5/20 | 0.85 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 0.85 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 0.85 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.85 |
| ▸ | RET | P07949 | 2/20 | 0.85 |
| ▸ | GAK | O14976 | 1/20 | 0.85 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.85 |
| ▸ | ULK1 | O75385 | 1/20 | 0.85 |
| ▸ | STK10 | O94804 | 1/20 | 0.85 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.85 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.85 |
| ▸ | LATS1 | O95835 | 1/20 | 0.85 |
| ▸ | PAK4 | O96013 | 1/20 | 0.85 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.85 |
| ▸ | LCK | P06239 | 1/20 | 0.85 |
| ▸ | CDK1 | P06493 | 1/20 | 0.85 |
| ▸ | APRT | P07741 | 1/20 | 0.85 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.85 |
| ▸ | NQO2 | P16083 | 1/20 | 0.85 |
| ▸ | FECH | P22830 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Crenolanib SCHEMBL4681285 | 1.00 | FLT3 (0.85) | FLT3IRAK4RETGAKRIPK2 | |
| Crenolanib SCHEMBL29352554 | 1.00 | FLT3 (0.85) | FLT3IRAK4RETGAKRIPK2 | |
| Crenolanib SCHEMBL2730601 | 0.92 | FLT3 (1.00) | FLT3IRAK4RETGAKRIPK2 | |
| Crenolanib SCHEMBL29350134 | 0.92 | FLT3 (1.00) | FLT3IRAK4RETGAKRIPK2 | |
| Crenolanib SCHEMBL30002138 | 0.92 | FLT3 (1.00) | FLT3IRAK4RETGAKRIPK2 | |
| Crenolanib SCHEMBL29352568 | 0.92 | FLT3 (1.00) | FLT3IRAK4RETGAKRIPK2 | |
| SCHEMBL24139877 | 0.88 | FLT3 (0.72) | FLT3IRAK4RETGAKRIPK2 | |
| SCHEMBL4681289 | 0.86 | FLT3 (0.71) | FLT3IRAK4RETGAKRIPK2 | |
| SCHEMBL24556935 | 0.86 | FLT3 (0.69) | FLT3IRAK4RETGAKRIPK2 | |
| SCHEMBL25862336 | 0.86 | FLT3 (0.68) | FLT3IRAK4RETGAKRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743086-A2 | TREATING MYELOID DISORDERS | Mayo Foundation for Medical Education and Research (US) | 2026-05-20 | — | — | EP | claimed |
| US-12534764-B2 | Crenolanib for treating FLT3 mutated proliferative disorders associated mutations | AROG PHARMACEUTICALS, INC. (US) | 2026-01-27 | — | — | US | claimed |
| US-20250345322-A1 | NOVEL COMBINATION THERAPY OF CRENOLANIB AND APOPTOSIS PATHWAY AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AROG PHARMACEUTICALS INC (US) | 2025-11-13 | — | — | US | claimed |
| US-20250305063-A1 | Crenolanib for Treating FLT3 Mutated Proliferative Disorders Associated Mutations | AROG PHARMACEUTICALS, INC. | 2025-10-02 | — | — | US | claimed |
| US-12404555-B2 | Crenolanib for treating FLT3 mutated proliferative disorders associated mutations | AROG PHARMACEUTICALS, INC. (US) | 2025-09-02 | — | — | US | claimed |
| US-12383549-B2 | Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders | AROG PHARMACEUTICALS, INC. (US) | 2025-08-12 | — | — | US | claimed |
| US-20250161293-A1 | CRENOLANIB FOR TREATING FLT3 MUTATED PROLIFERATIVE DISORDERS RELAPSED/REFRACTORY TO PRIOR TREATMENT | AROG PHARMACEUTICALS, INC. | 2025-05-22 | — | — | US | claimed |
| US-12295948-B2 | Crenolanib for treating FLT3 mutated proliferative disorders relapsed/refractory to prior treatment | AROG PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | claimed |
| US-20250032475-A1 | Crenolanib for Treating FLT3 Mutated Proliferative Disorders | AROG PHARMACEUTICALS, INC. | 2025-01-30 | — | — | US | claimed |
| WO-2025015263-A2 | TREATING MYELOID DISORDERS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2025-01-16 | — | — | WO | claimed |
| US-20220409610-A1 | Crenolanib for Treating FLT3 Mutated Proliferative Disorders | AROG PHARMACEUTICALS, INC. | 2022-12-29 | — | — | US | claimed |
| US-11524006-B2 | Crenolanib for treating TRK kinase associated proliferative disorders | AROG PHARMACEUTICALS, INC. (US) | 2022-12-13 | — | — | US | claimed |
| US-11458131-B2 | Crenolanib for treating FLT3 mutated proliferative disorders | AROG PHARMACEUTICALS, INC. (US) | 2022-10-04 | — | — | US | claimed |
| EP-4051282-A1 | METHODS OF TREATING CANCER IN BIOMARKER-IDENTIFIED PATIENTS WITH INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2022-09-07 | — | — | EP | claimed |
| US-20220218694-A1 | CRENOLANIB FOR TREATING FLT3 MUTATED PROLIFERATIVE DISORDERS ASSOCIATED MUTATIONS | AROG PHARMACEUTICALS, INC. | 2022-07-14 | — | — | US | claimed |
| US-20220133710-A1 | NOVEL COMBINATION THERAPY OF CRENOLANIB AND APOPTOSIS PATHWAY AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AROG PHARMACEUTICALS, INC. | 2022-05-05 | — | — | US | claimed |
| US-20220079933-A1 | CRENOLANIB FOR TREATING TRK KINASE ASSOCIATED PROLIFERATIVE DISORDERS | AROG PHARMACEUTICALS, INC. | 2022-03-17 | — | — | US | claimed |
| US-20220079934-A1 | CRENOLANIB FOR TREATING PAIN | AROG PHARMACEUTICALS, INC. | 2022-03-17 | — | — | US | claimed |
| US-20220047577-A1 | CRENOLANIB FOR TREATING PDGFR ALPHA MUTATED PROLIFERATIVE DISORDERS | AROG PHARMACEUTICALS, INC. | 2022-02-17 | — | — | US | claimed |
| US-20220047574-A1 | CRENOLANIB FOR TREATING PDGFR ALPHA MUTATED PROLIFERATIVE DISORDERS | AROG PHARMACEUTICALS, INC. | 2022-02-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250032475-A1 | Crenolanib for Treating FLT3 Mutated Proliferative Disorders | FLT3, FLT1, RET | FLT3 1/4885PDGFRB 8/4885PDGFRA 9/4885 |
| US-20250345322-A1 | NOVEL COMBINATION THERAPY OF CRENOLANIB AND APOPTOSIS PATHWAY AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CCAR2, BAX, DUSP22 | FLT3 2173/4885PDGFRB 164/4885PDGFRA 278/4885 |
| US-20250305063-A1 | Crenolanib for Treating FLT3 Mutated Proliferative Disorders Associated Mutations | FLT3, RET, CSF1R | FLT3 1/4885PDGFRB 15/4885PDGFRA 14/4885 |
| US-20220079933-A1 | CRENOLANIB FOR TREATING TRK KINASE ASSOCIATED PROLIFERATIVE DISORDERS | NTRK1, NTRK3, NTRK2 | FLT3 346/4885PDGFRB 16/4885PDGFRA 17/4885 |
| US-12295948-B2 | Crenolanib for treating FLT3 mutated proliferative disorders relapsed/refractory to prior treatment | FLT3, RET, MKI67 | FLT3 1/4885PDGFRB 24/4885PDGFRA 31/4885 |
| US-11458131-B2 | Crenolanib for treating FLT3 mutated proliferative disorders | FLT3, FLT1, RET | FLT3 1/4885PDGFRB 8/4885PDGFRA 9/4885 |
| US-20220079934-A1 | CRENOLANIB FOR TREATING PAIN | OPRL1, OPRK1, CCL11 | FLT3 775/4885PDGFRB 55/4885PDGFRA 114/4885 |
| US-12404555-B2 | Crenolanib for treating FLT3 mutated proliferative disorders associated mutations | FLT3, RET, CSF1R | FLT3 1/4885PDGFRB 15/4885PDGFRA 14/4885 |
| US-12534764-B2 | Crenolanib for treating FLT3 mutated proliferative disorders associated mutations | FLT3, NUP188, KPNB1 | FLT3 1/4885PDGFRB 215/4885PDGFRA 234/4885 |
| US-20250161293-A1 | CRENOLANIB FOR TREATING FLT3 MUTATED PROLIFERATIVE DISORDERS RELAPSED/REFRACTORY TO PRIOR TREATMENT | FLT3, RET, MKI67 | FLT3 1/4885PDGFRB 24/4885PDGFRA 31/4885 |
| US-20220047574-A1 | CRENOLANIB FOR TREATING PDGFR ALPHA MUTATED PROLIFERATIVE DISORDERS | PDGFRA, PDGFRB, PDGFA | FLT3 32/4885PDGFRB 2/4885PDGFRA 1/4885 |
| US-11524006-B2 | Crenolanib for treating TRK kinase associated proliferative disorders | NTRK1, NTRK3, NTRK2 | FLT3 346/4885PDGFRB 16/4885PDGFRA 17/4885 |
| US-12383549-B2 | Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders | CCAR2, BAX, TP53 | FLT3 2042/4885PDGFRB 177/4885PDGFRA 273/4885 |
| US-20220133710-A1 | NOVEL COMBINATION THERAPY OF CRENOLANIB AND APOPTOSIS PATHWAY AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CCAR2, BAX, DUSP22 | FLT3 2173/4885PDGFRB 164/4885PDGFRA 278/4885 |
| US-20220409610-A1 | Crenolanib for Treating FLT3 Mutated Proliferative Disorders | FLT3, FLT1, RET | FLT3 1/4885PDGFRB 8/4885PDGFRA 9/4885 |
| US-20220218694-A1 | CRENOLANIB FOR TREATING FLT3 MUTATED PROLIFERATIVE DISORDERS ASSOCIATED MUTATIONS | FLT3, RUNX1, RET | FLT3 1/4885PDGFRB 31/4885PDGFRA 62/4885 |
| US-20220047577-A1 | CRENOLANIB FOR TREATING PDGFR ALPHA MUTATED PROLIFERATIVE DISORDERS | PDGFRA, PDGFRB, PDGFA | FLT3 32/4885PDGFRB 2/4885PDGFRA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.